Screening for early AL amyloidosis in people with precursor blood conditions
Studies a screening approach to find AL amyloidosis early in at-risk adults.
Plain-language title generated from the registry record
Registry title: Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Key facts
- Where
- Bari, Catania, Pavia, and Torino, ItalySee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06383143, who can take part
Where in Italy
- Azienda Ospedaliera Policlinico ConsorzialeBari, ItalyTaking people
- Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"Catania, ItalyTaking people
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
- EMATOLOGIA - Città della Scienza e Salute - TorinoTorino, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Trial code
- NCT06383143
- Record updated
- 16 April 2026
- Original description
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:Read full original descriptionShow less
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:
1. Implement a biomarker-based screening strategy to promote early diagnosis of AL amyloidosis among at-risk patients, including patients with monoclonal gammopathy of undetermined significance, MGUS, and altered free light chain ratio (aFLCR), and patients with smoldering multiple myeloma (SMM) 2. Expedite and facilitate patients' referral and their enrollment in ongoing pre-clinical/clinical studies, also to reflect a broader spectrum of the real-world population of patients with AL amyloidosis in Italy; 3. Investigate the clinical utility of novel diagnostic technologies, including light chain sequencing and N-glycosylation analysis
Inclusion: diagnosis of MGUS with altered FLCR or SMM; treatment-naïve; age ≥18 years; ability to understand and willingness to sign an informed consent; planned follow-up at participating center; diagnosis of systemic AL amyloidosis; treatment-naïve; age ≥18 years; ability to understand and willingness to sign an informed consent; planned follow-up at participating center.
Exclusion: Previous treatment for monoclonal gammopathies; PART B; previous treatment for AL amyloidosis; Diagnosis of symptomatic monoclonal gammopathies; non-AL amyloidosis.
PART A.